Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Table 1 Classification of subgroups defined by clinical and physiologic indicators of less-advanced disease or advanced disease at baseline

Clinical measure	Subgroup with less-advanced disease	Subgroup with advanced disease
GAP stage	I	II/III
% predicted FVC, %	> 80	≤ 80
% predicted DL_CO, %	> 40	≤ 40
CPI	≤ 45	> 45
SGRQ total score	≤ 40	> 40

CPI composite physiologic index, DL_CO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, GAP gender, age and physiology, SGRQ St George’s respiratory questionnaire

ISSN: 1465-993X